A Functional Polymorphism of the μ-Opioid Receptor Gene is Associated with Naltrexone Response in Alcohol-Dependent Patients
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
This study examined the association between two specific polymorphisms of the gene encoding the mu-opioid receptor and treatment outcomes in alcohol-dependent patients who were prescribed naltrexone or placebo. A total of 82 patients (71 of European descent) who were randomized to naltrexone and 59 who were randomized to placebo (all of European descent) in one of three randomized, placebo-controlled clinical trials of naltrexone were genotyped at the A(+118)G (Asn40Asp) and C(+17)T (Ala6Val) SNPs in the gene encoding the mu-opioid receptor (OPRM1). The association between genotype and drinking outcomes was measured over 12 weeks of treatment. In subjects of European descent, individuals with one or two copies of the Asp40 allele treated with naltrexone had significantly lower rates of relapse (p=0.044) and a longer time to return to heavy drinking (p=0.040) than those homozygous for the Asn40 allele. There were no differences in overall abstinence rates (p=0.611), nor were there differences in relapse rates or abstinence rates between the two genotype groups among those assigned to placebo. These preliminary results are consistent with prior literature demonstrating that the opioid system is involved in the reinforcing properties of alcohol and that allelic variation at OPRM1 is associated with differential response to a mu-receptor antagonist. If replicated, these results would help to identify alcohol-dependent individuals who may be most likely to respond to treatment wit…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An initial retrospective analysis of NTX trials found that OPRM1 influenced treatment response, such that individuals with the Asp40 variant (G allele) receiving NTX had a longer time until the first heavy drinking day and were half as likely to relapse compared to those homozygous for the Asn40 variant (A allele) [92].”
From Relapse prevention for addictive behaviors (2011) · cites this paper as [92]
In the citing paper
“Interestingly, both human A118G subjects and Rhesus C77G subjects are more likely to respond positively to opioid antagonist therapy for alcoholism, which suggests that the differences in receptor properties may be a direct physiological mechanism for the increased risk for alcoholism (Oslin et al 2003).”
From The behavioral, anatomical and pharmacological parallels between social attachment, love and addiction (2012) · cites this paper as Oslin et al 2003
Citations
Cites
(1996) · Cited by 6,884
The fifth edition of the addiction severity index
McLellan, A. T., Kushner, H., Metzger, D., Peters, R., Smith, I., Grissom, G., Pettinati, H., & Argeriou, M. (1992) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(92)90062-s · Cited by 4,222 · cited 1×
“The Addiction Severity Index (ASI) was used to measure the severity of alcoholrelated problems during the pretreatment period (McLellan et al, 1980, 1992).”
MethodSelf-citationSobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110 · cited 1×
“The Time Line Follow-Back (TLFB) method measured alcohol consumption (Sobell et al, 1988; Sobell and Sobell, 1992) during the pretreatment and treatment periods.”
MethodMcLELLAN, A. T., LUBORSKY, L., WOODY, G. E., & O??BRIEN, C. P. (1980) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198001000-00006 · Cited by 3,188
Naltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
Self-citationNew Data from the Addiction Severity Index Reliability and Validity in Three Centers
McLELLAN, A. T., LUBORSKY, L., CACCIOLA, J., GRIFFITH, J., EVANS, F., BARR, H. L., & OʼBRIEN, C. P. (1985) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198507000-00005 · Cited by 1,503 · cited 1×
“…lifetime and recent (past 30 days) severity of problems in seven areas of biopsychosocial functioning (represented by component scores): medical status, employment and self-support, alcohol use, drug use, legal status, family and social relations, and psychiatric symptoms (McLellan et al, 1985).”
BackgroundSelf-citationNaltrexone and Coping Skills Therapy for Alcohol Dependence: A Controlled Study
O'Malley, S. S. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110045007 · Cited by 1,487 · cited 4×
“Although this definition of heavy drinking has been used in a number of pharmacotherapy trials (O’Malley et al, 1992; Volpicelli et al, 1992; Anton, 1996; Kranzler and VanKirk, 2001), both higher and lower levels of consumption could be considered significant.”
BackgroundMethodInfluentialBond, C., LaForge, K. S., Tian, M., Melia, D., Zhang, S., Borg, L., Gong, J., Schluger, J., Strong, J. A., Leal, S. M., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.16.9608 · Cited by 1,074 · cited 3×
“…association between OPRM1 sequence variation and the presence of alcohol and/or drug dependence (Bergen et al, 1997; Berrettini et al, 1997; Bond et al, 1998; Kranzler et al, 1998; Sander et al, 1998; Gelernter et al, 1999; Town et al, 1999; Hoehe et al, 2000; Franke et al, 2001;…”
BackgroundInfluentialSOBELL, L. C., SOBELL, M. B., LEO, G. I., & CANCILLA, A. (1988) · British Journal of Addiction · doi:10.1111/j.1360-0443.1988.tb00485.x · Cited by 776 · cited 1×
“The Time Line Follow-Back (TLFB) method measured alcohol consumption (Sobell et al, 1988; Sobell and Sobell, 1992) during the pretreatment and treatment periods.”
MethodNaltrexone in the Treatment of Alcohol Dependence
Krystal, J. H., Cramer, J. A., Krol, W. F., Kirk, G. F., & Rosenheck, R. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011127 · Cited by 618 · cited 1×
“…advantage of naltrexone over placebo (O’Malley et al, 1992; Volpicelli et al, 1992; Oslin et al, 1997; Chick et al, 2000; Anton et al, 2001; Monti et al, 2001; Morris et al, 2001), other studies have failed to show a significant drugplacebo difference (Kranzler et al, 2000; Krystal et al, 2001).”
Background
Research works printed but not linked: 2
- Thomas C, Wallack S, Swift R, Bishop C, McCarty D, Simoni-Wastila L (2001). Adoption of naltrexone in alcoholism treatment. J Addict Dis 20: 180.
- Volpicelli JR, Pettinati HM, McLellan AT, O'Brien CP (1997). BRENDA Manual: Compliance Enhancement Techniques with Pharmacotherapy for Alcohol and Drug Dependence. Guilford press: Philadelphia.
Cited by
Items 401–500 of 572
OPRM1 genotype and naltrexone response in depressed alcohol-dependent patients
Foulds, J., Ton, K. N. T., Kennedy, M. A., Adamson, S. J., Mulder, R., & Sellman, J. D. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000128 · Cited by 10
Primary Care Providers' Interest in Using a Genetic Test to Guide Alcohol Use Disorder Treatment
Williams, E. C., Young, J. P., Achtmeyer, C. E., & Hendershot, C. S. (2016) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2016.07.009 · Cited by 10
Pharmacotherapy for alcohol dependence: A stratified approach
Thompson, A., Owens, L., Pushpakom, S. P., Faizal, M. A., & Pirmohamed, M. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.010 · Cited by 12
“The use of sensitivity analysis revealed that removal of any one of three studies (Anton et al., 2008; Kim et al., 2009; Oslin et al., 2003) from the meta-analysis resulted in a loss of statistical significance, probably due to the non- AC C EP TE D M AN U SC R IP T significant outcomes reported in…”
MethodAkala, E. O., Wang, H., & Adedoyin, A. B. (2008) · Neuropsychobiology · doi:10.1159/000159776 · Cited by 10
Marini, V., Fucile, C., Zuccoli, M. L., Testino, G., Sumberaz, A., Robbiano, L., Martelli, A., & Mattioli, F. (2012) · Addictive Behaviors · doi:10.1016/j.addbeh.2012.09.015 · Cited by 10
Adjunctive Pharmacotherapy in the Treatment of Alcohol and Drug Dependence
Swift, R. M., & Leggio, L. (2009) · Elsevier eBooks · doi:10.1016/b978-0-12-374348-0.00015-x · Cited by 11
Pedrosa, E., Kaushik, S., & Lachman, H. M. (2009) · Journal of Neurogenetics · doi:10.3109/01677060903305658 · Cited by 10
Swift, R. M., & Pettinati, H. M. (2005) · Journal of Studies on Alcohol Supplement · doi:10.15288/jsas.2005.s15.141 · Cited by 10
Self-citationSustained-release naltrexone for opioid dependence
Kornør, H., Lobmaier, P. P. K., & Kunøe, N. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006140.pub3 · Cited by 15
Effects of naltrexone on post-abstinence alcohol drinking in C57BL/6NCRL and DBA/2J mice
Tomie, A., Azogu, I., & Yu, L. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.03.002 · Cited by 10
Hendershot, C. S. (2014) · Addiction Science & Clinical Practice · doi:10.1186/1940-0640-9-20 · Cited by 10
Pharmacotherapy of Alcohol Dependence: Improving Translation from the Bench to the Clinic
Little, H. J., McKinzie, D. L., Setnik, B., Shram, M. J., & Sellers, E. M. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373861-5.00025-4 · Cited by 9
Hendershot, C. S., Dermody, S. S., Wardell, J. D., Zaso, M. J., Kennedy, J. L., & Stoner, S. A. (2020) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14300 · Cited by 9
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript treatment with naltrexone vs. placebo, relative to patients homozygous for the 118A variant (i.e., AA genotype; Anton et al., 2008, Oslin et al., 2003).”
MethodResultInfluentialThe opioid systems – Panacea and nemesis
Terenius, L. Y., & Johansson, B. A. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.04.001 · Cited by 9
On Blending Practice and Research
Kellogg, S. H., & Kreek, M. J. (2006) · Substance Abuse · doi:10.1300/j465v27n01_03 · Cited by 9
Genetics of Psychiatric Disorders
Nürnberger, J. I., Berrettini, W. H., & Niculescu, A. B. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-252-6_29 · Cited by 10
Self-citationNonhuman Primate Models of Drug and Alcohol Addiction
Platt, D. M., & Rowlett, J. K. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-381366-4.00018-3 · Cited by 8
Recent advances in the treatment of alcoholism
Pettinati, H. M., & Rabinowitz, A. R. (2005) · Clinical Neuroscience Research · doi:10.1016/j.cnr.2005.08.011 · Cited by 11
Self-citationProgress in Addiction Treatment: From One-Size-Fits-All to Medications and Treatment Matching
WOODY, G. E. (2014) · Substance Abuse · doi:10.1080/08897077.2014.898012 · Cited by 10
Erratum: The genetics of addiction—a translational perspective
Agrawal, A., Verweij, K. J. H., Gillespie, N. A., Heath, A. C., Lessov‐Schlaggar, C. N., Martin, N. G., Nelson, E. C., Slutske, W. S., Whitfield, J. B., & Lynskey, M. T. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.129 · Cited by 9
Translational Approaches to Medication Development
Bartlett, S. E., & Heilig, M. A. (2011) · Current topics in behavioral neurosciences · doi:10.1007/978-3-642-28720-6_132 · Cited by 8
From genetic studies to precision medicine in alcohol dependence
Sun, Y., Zhang, Y., Wang, F., Sun, Y., Shi, J., & Lu, L. N. (2015) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000202 · Cited by 8
“…the rs1799971 G allele had the best outcome when treated with naltrexone, with a trend toward a lower rate of relapse, a greater percentage of abstinent days, a longer abstinence time, and less nighttime drinking (Oslin et al., 2003; Anton et al., 2008; Kim et al., 2009; Chen et al., 2013).”
BackgroundPharmakologische Rückfallprophylaxe bei Alkoholabhängigkeit
Kiefer, F., & Löber, S. (2007) · Psychiatrie und Psychotherapie up2date · doi:10.1055/s-2007-986228 · Cited by 7
Pharmacogenetics of Addiction Therapy
Graham, D. P., Harding, M. J., & Nielsen, D. A. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2573-6_16 · Cited by 7
Strobel, B., McManus, L., Leong, S. H., Blow, F. C., Slaymaker, V. J., Berrettini, W. H., Gordon, A. J., O’Brien, C. P., & Oslin, D. W. (2013) · Alcohol and Alcoholism · doi:10.1093/alcalc/agt130 · Cited by 6
“Recent clinical studies of naltrexone have demonstrated the potential importance of genotyping as a predictor of treatment response (Oslin et al., 2003;Anton, 2008).”
BackgroundSelf-citationBall, D., Pembrey, M. E., & Stephens, D. (2007) · Elsevier eBooks · doi:10.1016/b978-012370624-9/50007-4 · Cited by 6
Pharmacogenetics of chemical addictions
Krupitsky, E. M., Akhmetova, E. A., & Asadullin, A. R. (2019) · V M BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY · doi:10.31363/2313-7053-2019-4-1-12-20 · Cited by 8
Wang, K., Duan, Y., Duan, W., Yu, Y., Zheng, N., Hu, J., He, J., Chen, H., & Liang, M. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.620489 · Cited by 6
Stasiak, A., & Fogel, W. A. (2008) · PubMed · Cited by 6
Genetics of Psychiatric Disorders
Nürnberger, J. I., Berrettini, W., & Niculescu, A. B. (2016) · Springer eBooks · doi:10.1007/978-1-4939-2528-5_29 · Cited by 7
Self-citationPharmacogenetics of Alcoholism: A Clinical Neuroscience Perspective
Ray, L. A., Courtney, K. E., Bujarski, S., & Squeglia, L. M. (2012) · Pharmacogenomics · doi:10.2217/pgs.11.173 · Cited by 6
“Some clinical studies of naltrexone have suggested improved clinical outcomes among Gallele carriers [13,14], with noted exceptions [15], and the purported mechanisms of action is greater naltrexone-induced blunting of alcohol “high” among these individuals [9].”
Lechner, W. V., Knopik, V. S., McGeary, J. E., Spillane, N. S., Tidey, J. W., McKee, S. A., Metrik, J., Leventhal, A. M., Rohsenow, D. J., & Kahler, C. W. (2015) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntv136 · Cited by 6
Misailidis, G., Ragia, G., Ivanova, D. D., Tavridou, A., & Manolopoulos, V. G. (2015) · Drug Metabolism and Personalized Therapy · doi:10.1515/dmdi-2015-0005 · Cited by 5
What does addiction medicine expect from neuroscience? From genes and neurons to treatment responses
Foll, B. L. (2016) · Progress in brain research · doi:10.1016/bs.pbr.2015.11.001 · Cited by 6
Nieto, S. J., Grodin, E. N., & Ray, L. A. (2020) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2020.1724510 · Cited by 5
Medication Treatment of Different Types of Alcoholism
Johnson, B. A. (2011) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.9.1.foc79 · Cited by 6
Pharmacogenomics of alcohol addiction: Personalizing pharmacologic treatment of alcohol dependence
Ragia, G., & Manolopoulos, V. G. (2014) · Hospital Pharmacology - International Multidisciplinary Journal · doi:10.5937/hpimj1403147r · Cited by 5
Pathological Gambling and Nicotine Dependence: Clinical Case Discussion
Grant, J. E., Black, D. W., Stein, D. J., & Potenza, M. N. (2009) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e3181a1cc36 · Cited by 6
“For example, an allelic variant of the gene encoding the mu-opioid receptor have been linked to naltrexone treatment outcome in alcohol dependence (Oslin et al., 2003) and nicotine dependence (Lerman et al., 2005), and it is a reasonable hypothesis that this allelic variant would also be associated…”
Penn/VA center for studies of addiction
O’Brien, C. P., McLellan, A. T., Childress, A. R., & WOODY, G. E. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.06.030 · Cited by 5
“N IH -PA Author M anuscript N IH -PA Author M anuscript N IH -PA Author M anuscript significantly better response to naltrexone than placebo (Oslin et al., 2003).”
BackgroundSelf-citationEvolving ‘-omics’ technologies in the drug development process
Pavelić, S. K., & Šaban, N. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.4.431 · Cited by 5
Neurobiologie und Genetik von Suchterkrankungen
Kiefer, F. (2010) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-010-1031-1 · Cited by 6
Endogenous Opiates, Addiction, and the Stress Response
Chong, R. Y., Uhart, M., & Wand, G. S. (2007) · Elsevier eBooks · doi:10.1016/b978-012370632-4/50007-3 · Cited by 5
de Bejczy, A., Addolorato, G., Aubin, H., Guiraud, J., Korpi, E. R., Nutt, D. J., Witkiewitz, K. A., & Söderpalm, B. (2024) · International review of neurobiology · doi:10.1016/bs.irn.2024.03.003 · Cited by 6
Pharmacological Treatment of Substance Abuse Disorders
Raby, W. N., Mariani, J. J., LEVIN, F. R., & Nunes, E. V. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch113 · Cited by 4
Potretzke, S., Robins, M. T., & Ryabinin, A. E. (2020) · Hormones and Behavior · doi:10.1016/j.yhbeh.2020.104676 · Cited by 4
Genetic Polymorphism in Alcohol-dependent Genes: A Review
Arunachalam, U., & Chandrasekaran, A. (2020) · SBV Journal of Basic Clinical and Applied Health Science · doi:10.5005/jp-journals-10082-02260 · Cited by 4
Genetics of Substance Use Disorders
Agrawal, A., & Lynskey, M. T. (2014) · Springer eBooks · doi:10.1007/978-1-4614-9509-3_7 · Cited by 4
Cholinergic mu-opioid receptor deletion alters reward preference and aversion-resistance
Beane, C., Lewis, D. G., Bruns, N., Pikus, K. L., Durfee, M. H., Zegarelli, R. A., Perry, T. W., Sandoval, O., & Radke, A. K. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110019 · Cited by 4
Traitements médicamenteux et psychothérapiques de l’alcoolodépendance
Cottencin, O. (2018) · La Presse Médicale · doi:10.1016/j.lpm.2018.07.001 · Cited by 4
Garbutt, J. C. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-252-6_14 · Cited by 6
O’Brien, C. P., Pettinati, H. M., & Oslin, D. W. (2006) · Birkhäuser-Verlag eBooks · doi:10.1007/3-7643-7305-9_6 · Cited by 4
Self-citationCommentary on Nelsonet al. (2010)
Barr, C. S. (2009) · Addiction Biology · doi:10.1111/j.1369-1600.2009.00182.x · Cited by 4
“Certainly, there is some evidence that this is the case for naltrexone response as it pertains to variation at the OPRM1 gene (Oslin et al. 2003; Anton et al. 2008; Barr et al. 2009b).”
BackgroundModels for alcohol dependence: A clinical perspective
Heilig, M. A., & Egli, M. (2005) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2005.11.004 · Cited by 4
Chapter 55. Treatment of Alcohol Use Disorder
Mason, B. J., Ritvo, E. C., & Bonci, A. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as55 · Cited by 3
The Role of Positron Emission Imaging (PET) in Understanding Addiction
Wong, D. F., Brašić, J. R., Gean, E. G., & Nandi, A. (2013) · Wiley eBooks · doi:10.1002/9781118384404.ch24 · Cited by 3
[Commentary] MATCHING CLIENTS TO PSYCHOSOCIAL TREATMENTS: AT THE CUSP OF HOPE AND EVIDENCE?
Finney, J. W. (2008) · Addiction · doi:10.1111/j.1360-0443.2007.02117.x · Cited by 3
Naltrexone in Smoking Cessation: A Review of the Literature and Future Directions
King, A. C., Torello, R., Krishnan‐Sarin, S., & O’Malley, S. S. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-197-0_17 · Cited by 4
ÁLCOOL E NEURODESENVOLVIMENTO: ASPECTOS GENÉTICOS E FARMACOLÓGICOS
Wong, D. V. T., Ferreira, J. R., Fonteles, M. M. F., Viana, G. S. D. B., de Souza, F. C. F., & Vasconcelos, S. M. M. (2008) · Revista Eletrônica de Farmácia · doi:10.5216/ref.v5i1.4609 · Cited by 13
The human mu opioid receptor gene in addictions
Berettimi, W. (2005) · Clinical Neuroscience Research · doi:10.1016/j.cnr.2005.08.003 · Cited by 3
Leggio, L., & Schwandt, M. L. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000790 · Cited by 3
“The functional OPRM1 polymorphism A118G plays an important role in the effects of naltrexone on alcohol consumption, with G-allele carriers responding more positively to treatment than A-allele homozygotes (Oslin et al., 2003; Anton et al., 2008; Barr et al., 2010; Kranzler et al., 2013).”
BackgroundImaging Human Brain Opioid Receptors: Applications to Substance Use Disorders
Greenwald, M. K., & Steinmiller, C. L. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-197-0_3 · Cited by 4
Impact of bidirectional translational research on treatment of addiction
Kreek, M. J. (2005) · Clinical Neuroscience Research · doi:10.1016/j.cnr.2005.08.008 · Cited by 3
Genetics, Stress, and the Risk for Addiction
Enoch, M. (2007) · Elsevier eBooks · doi:10.1016/b978-012370632-4/50009-7 · Cited by 5
Toward a rational selection of treatment for addiction
O’Brien, C. P. (2007) · Current Psychiatry Reports · doi:10.1007/s11920-007-0058-y · Cited by 2
Self-citationGenetic Factors Underlying Treatment Resistance in Psychiatry
Maron, E., Lan, C., & Nutt, D. J. (2018) · Springer eBooks · doi:10.1007/978-981-10-4358-1_3 · Cited by 2
Deciphering the Role of Genetics in Alcohol Use Disorder
Legaki, E., Koutromanos, I., Mantonakis, L., Tzavellas, E., & Maria, G. (2024) · Springer eBooks · doi:10.1007/978-3-031-32035-4_119-1 · Cited by 2
van Amsterdam, J., & van den Brink, W. (2025) · Alcohol · doi:10.1016/j.alcohol.2025.06.004 · Cited by 2
Pharmacotherapy of Alcohol and Drug Dependence
Swift, R. M., & Aoun, E. G. (2014) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-014-0029-7 · Cited by 2
Clinical Use of Opioid Antagonists in the Treatment of Alcohol Dependence
Anton, R. F. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-197-0_19 · Cited by 2
Predictors of Treatment Outcome in Disordered Gambling
Ledgerwood, D. M., Loree, A. M., & Lundahl, L. H. (2013) · Wiley eBooks · doi:10.1002/9781118316078.ch13 · Cited by 3
Naltrexone Pharmacogenetics in Alcohol-dependent Patients
Berrettini, W. H. (2008) · Psychiatric Annals · doi:10.3928/00485713-20080601-01 · Cited by 2
Self-citationFemenía, T., Portillo, P. A., Pérez‐Ortiz, J. M., Aracil-Fernández, A., Rubio, G., & Manzanares, J. (2009) · The Open Neuropsychopharmacology Journal · doi:10.2174/1876523800902020053 · Cited by 2
“These results are discrepant with the report showing that naltrexone preferentially protected against relapse in Asp-carrying alcohol-dependent individuals [167].”
BackgroundResultLes innovations thérapeutiques en alcoologie
Paillé, F. (2018) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2018.08.004 · Cited by 2
Lötsch, J., & Mogil, J. S. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-993-2_17 · Cited by 2
Polimorfismos del ADN en el alcoholismo
Pastor, I., & Laso, F. J. (2005) · Medicina Clínica · doi:10.1157/13072844 · Cited by 2
Future perspectives on relapse prevention
Spanagel, R., & Mann, K. F. (2006) · Birkhäuser-Verlag eBooks · doi:10.1007/3-7643-7305-9_20 · Cited by 2
Pharmacological Long-Term Treatment of Alcohol Use Disorders
Mann, K. F., & Kiefer, F. (2014) · Springer eBooks · doi:10.1007/978-88-470-5322-9_12 · Cited by 1
Bergasa, N. V. (2022) · Medical Hypotheses · doi:10.1016/j.mehy.2022.110925 · Cited by 1
Farahbakhsh, Z. Z., Brown, A. R., Nolan, S. O., Mukerjee, S., & Siciliano, C. A. (2026) · Communications Medicine · doi:10.1038/s43856-025-01369-6 · Cited by 1
A review of the existing pharmacogenomic literature of naltrexone for use in alcohol use disorder
Counts, C. J., Ali, N., Ali, S., Muhammad, K. A., Diop, F., Sims, K., Ajoku, A., & Santos, C. (2025) · Pharmacogenomics · doi:10.1080/14622416.2026.2613634 · Cited by 1
Current and Future Directions of Research on Stress and Addictive Behaviors
Al’Absi, M. (2007) · Elsevier eBooks · doi:10.1016/b978-012370632-4/50021-8 · Cited by 1
Pharmacotherapy for alcohol dependence.
Wortman, S. P., Rabinowitz, A. R., & Oslin, D. W. (2005) · PubMed · Cited by 1
Self-citationOslin, D. W. (2007) · Humana Press eBooks · doi:10.1007/978-1-59259-960-8_9 · Cited by 1
Self-citationPharmacogenetics of Opioid and Alcohol Addiction
Callejas, D. G., Cañadas‐Garre, M., Aguilera, J., Jiménez‐Varo, E., & Hernández, M. Á. C. (2013) · Springer eBooks · doi:10.1007/978-81-322-1184-6_17 · Cited by 1
Farmacogenética en el tratamiento del alcoholismo
Marcos, M., Pastor, I., & Guzmán, F. J. L. (2012) · Actualidad en farmacología y terapéutica · Cited by 1
Alcohol‐Use Disorders – Treatment and Management
Passetti, F., & Drummond, C. (2009) · Wiley eBooks · doi:10.1002/9780470975084.ch12 · Cited by 1
Carsten, K., & Selena, E. (2012) · InTech eBooks · doi:10.5772/32239 · Cited by 1
“…opioid peptide receptor (MOP-R) with a mutation at A118G (Asn40Asp) have greater euphoric responses to alcohol, increased pain thresholds, greater susceptibility to AUDs and greater responses treatment with naltrexone (Anton et al., 2008; Bart et al., 2005; Oroszi et al., 2009; Oslin et al., 2003).”
BackgroundThe implications of genetic research on alcohol dependence for prevention and treatment
Mathews, R. R. S., Carter, A., & Hall, W. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139058971.003 · Cited by 1
Imaging Genetics and Addiction
Srivastava, V., & Goldman, D. A. (2011) · Wiley eBooks · doi:10.1002/9781119998938.ch12 · Cited by 1
Pharmacogenetics of the µ-Opioid Receptor and the Treatment of Addictions
Ray, L. A., MacKillop, J. M., & Hutchison, K. E. (2007) · Personalized Medicine · doi:10.2217/17410541.4.2.217 · Cited by 1
“Regarding theoretical rationale, for example, the OPRM1 genotype examined by Munafò and colleagues has been tested in the context of responsivity to naltrexone, an opioid antagonist thought to act selectively for μ-opioid receptors and used as a treatment for alcohol-use disorders [10,11,16].”
BackgroundThe Genetics of Alcoholism and Other Addictive Disorders
Goldman, D. A., & Ducci, F. (2009) · Springer eBooks · doi:10.1007/978-3-540-37654-5_30 · Cited by 1
Using Genetics to Improve Addiction Treatment Outcomes
Allenby, C. E., & Falcone, M. (2017) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-017-0106-9 · Cited by 1
Ethical Guidelines for Genetic Research on Alcohol Addiction and Its Applications
Chapman, A. R., Carter, A., Kaplan, J. M., Morphett, K., & Hall, W. (2018) · Kennedy Institute of Ethics journal · doi:10.1353/ken.2018.0000 · Cited by 1
NEUROLOGICAL MANIFESTATIONS OF PRIMARY CHOLESTATIC LIVER DISEASES
Shulpekova, J. O., Shirokova, E. N., Rusyaev, V. Y., & Damulin, I. V. (2018) · Russian Medicine · doi:10.18821/0869-2106-2018-24-4-213-219 · Cited by 1
Roşca, A., & Alexinschi, O. (2019) · Psihiatru ro · doi:10.26416/psih.56.1.2019.2280 · Cited by 1
Jones, S., & Banaszkiewicz, P. A. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108686624.028 · Cited by 1
Gendy, M. N. S., Zai, C. C. H., Foll, B. L., & Kennedy, J. L. (2019) · The Canadian Journal of Addiction · doi:10.1097/cxa.0000000000000069 · Cited by 1
Wolf, M. E. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-374947-5.00061-4 · Cited by 4
Differenzielle pharmakologische Rückfallprophylaxe bei Alkoholabhängigkeit
Mutschler, J., & Kiefer, F. (2011) · Journal für Kardiologie (Krause & Pachernegg GmbH) · doi:10.5167/uzh-58343 · Cited by 1
“Patienten mit ein oder zwei Kopien des Asp40-Allels zeigten unter Behandlung mit Naltrexon signifikant geringere Rückfallraten als homozygote Asn40-Allelträger [52, 53].”
BackgroundReply to Comments by Mr Martin and Dr Beresford
Suh, J. J., Gallis, T. L., Kampman, K. M., & Pettinati, H. M. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000280313.96613.72 · Cited by 1
Self-citation
Metadata
- Authors
- Oslin, D. W., Berrettini, W., Kranzler, H. R., Pettinati, H., Gelernter, J., Volpicelli, J. R., & O'Brien, C. P.
- Affiliations
- University of Pennsylvania (US)
- University of Connecticut (US)
- Yale University (US)
- Corresponding author
- Oslin, David W
- Venue
- Neuropsychopharmacology
- Published
- 2003-04-23
- Volume
- 28
- Issue
- 8
- Pages
- 1546-1552
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2074406420
- Cited by
- 571
- References
- 50
- Citations by year
- 2026: 2 · 2025: 10 · 2024: 4 · 2023: 3 · 2022: 7 · 2021: 9 · 2020: 13 · 2019: 18 · 2018: 13 · 2017: 13 · 2016: 20 · 2015: 31 · 2014: 36 · 2013: 34 · 2012: 58
- FWCI
- 10.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- University of Pennsylvania
- National Alliance for Research on Schizophrenia and Depression
- National Institutes of Health (5r01aa011062-05, AA03510)
- U.S. Public Health Service
- National Institute on Alcohol Abuse and Alcoholism (AA11330, AA-07517, R01AA011330, AA 13736, AA-03510, K24AA013736, AA 11062)
- National Institute of Mental Health (K08MH001599, MH 01599)
- National Institute on Drug Abuse (R01DA014008, DA 11385, DA 14008, DA001586)
- National Center for Research Resources (RR-06192, M01RR006192)
- NIH Clinical Center
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- mu-opioid receptor, OPRM1, naltrexone, alcoholism, genetic polymorphism, treatment response, relapse, abstinence, opioid system, pharmacogenetics
- MeSH terms
- Adult, Alcoholism, Female, Gene Frequency, Humans, Male, Middle Aged, Naltrexone, Polymorphism, Genetic, Confidence Intervals, Logistic Models, Odds Ratio, Survival Analysis, Receptors, Opioid, mu
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.